Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Miami Myeloma MRD 2024

09 May 2024 | Virtual Meeting

Miami Myeloma MRD 2024

09 May 2024 | Virtual Meeting

The Miami Myeloma MRD 2024 Meeting was hosted by the Myeloma Institute at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation for Multiple Myeloma, with VJHemOnc as official media partner. Explore presentations and discussions with leading experts below.

Current era MRD conversation between physician & patient Current & emerging technologies for tracking MRD Perspectives on available & new MRD assays FDA chat – what is happening in MRD in myeloma; what is next? MRD testing in the real world MRD in the real world discussion

SESSION I: Current era of MRD testing

Pieter Sonneveld
PERSEUS: MRD negativity in newly dx myeloma when using Dara-RVd
Pieter Sonneveld Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
Francesca Gay
ISKIA: MRD negativity in high-risk newly dx myeloma when using Isa-KRd
Francesca Gay University of Turin, Turin, Italy
Fredrik Schjesvold
REMNANT: treating myeloma at MRD relapse?
Fredrik Schjesvold Oslo University Hospital, Oslo, Norway
Martin Kaiser
MRD and plasma cell dynamics after CAR T-cells in myeloma
Martin Kaiser The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom

Live discussion – how to have an MRD conversation between physician and patient: Yelak Biru (IMF), Joseph Mikhael and Ola Landgren

Live discussion – how to have an MRD conversation between physician and patient: Yelak Biru (IMF), Joseph Mikhael and Ola Landgren

SESSION II: Current and emerging technologies for tracking MRD in myeloma

Sacha Gnjatic
Single-cell analysis of myeloma through the Immune Atlas
Sacha Gnjatic Mount Sinai, New York City, NY, United States
Katie Thoren
Updates on individualized serum peptides for MRD tracking
Katie Thoren University of Miami, Miami, FL, United States
Hitomi Hosoya
Ultrasensitive detection of circulating tumor DNA using CAPP sequencing
Hitomi Hosoya Stanford Medicine, Stanford, CA, United States
Irene Ghobrial
Whole genome sequencing of circulating myeloma cells in the blood
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States
Live discussion – perspectives on available and new MRD assays in myeloma: George Mulligan (MMRF) and Ola Landgren
Fireside chat with the FDA – what is happening in MRD in myeloma; what is next?: Nicole Gormley (FDA) and Ola Landgren

SESSION III: Myeloma MRD testing in the real world?

Luciano Costa
Updates on the MASTER trial treatment cessation study
Luciano Costa UAB School of Medicine, Birmingham, AL, United States
Benjamin Derman
Updates on the Chicago treatment cessation study
Benjamin Derman University of Chicago Medical Center, Chicago, IL, United States
Neha Korde
Updates on the MSKCC treatment cessation study
Neha Korde Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Charlotte Pawlyn
UK NCRI Myeloma XI trial; (when) can you stop maintenance therapy?
Charlotte Pawlyn The Institute of Cancer Research, London, United Kingdom
Live discussion: using MRD in the real world: Jennifer Ahlstrom (HealthTree) and Ola Landgren

The Miami Myeloma MRD 2024 Meeting was hosted by:

In collaboration with:

Supported by:

The content of VJHemOnc is intended for healthcare professionals